<DOC>
	<DOCNO>NCT01644721</DOCNO>
	<brief_summary>Background : All observational study randomise control trial ( RCT ) suggest early measles vaccine ( MV ) , particular early two-dose strategy , much well effect overall mortality later MV . These result suggest MV non-measles related beneficial effect child survival . Objective : To evaluate two-site RCT effect child survival health indicator two-dose measles vaccination schedule provide additional dose Edmonston-Zagreb ( EZ ) MV soon possible 4 month age well standard measles vaccine 9 month age . The trial plan Guinea-Bissau Burkina Faso . The investigator test 40-43 % reduction mortality site separately 32 % reduction overall . Based result RCT , investigator assess cost-effectiveness intervention . Design , Guinea-Bissau : Newborns follow Health Demographic Surveillance System ( HDSS ) Bandim Health Project . Information routine campaign vaccination collect regularly home visit health centre register . Four week receive third dose pentavalent vaccine ( Penta3 ) , child eligible enrollment trial severely ill . Eligible child invite take part trial . Provided parental informed consent give , child randomise MV 4 9 month age 9 month . Cost estimate base consumption service average cost per unit . The incremental cost effectiveness ratio calculate . Sample size , follow-up analysis : To detect 40 % reduction overall mortality site investigator intend enroll least 3,750 child Guinea-Bissau . The child follow survival hospitalisation 3 year age end study three year . The investigator analyse effect site combine ; sex season ; possible interaction intervention like campaign drug , vaccine micronutrient explore . Antibody study : 450 child enrol subgroup study examine effect maternal antibody level subsequent antibody response MV . The child follow 24 month age sample collect 4 , 9 24 month age .</brief_summary>
	<brief_title>Trial Additional Measles Vaccine Reduce Child Mortality</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children receive third dose pentavalent vaccine least 28 day enrolment 4 6 month old belong household exist HDSS Children serious malformation severely sick ( need hospitalisation ) high fever ( &gt; 38.5 C axillary temperature ) severely malnourish ( midupperarmcircumference ( MUAC ) &lt; 110 mm and/or bilateral peripheral oedema ) receive neonatal vitamin A supplementation whose parents/guardians state intend permanently move study area child reach 9 month age</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Child mortality</keyword>
	<keyword>Measles vaccine</keyword>
	<keyword>Non-specific effect</keyword>
</DOC>